image
Healthcare - Biotechnology - NASDAQ - US
$ 2.08
8.9 %
$ 75.1 M
Market Cap
-0.47
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one INO stock under the worst case scenario is HIDDEN Compared to the current market price of 2.08 USD, Inovio Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one INO stock under the base case scenario is HIDDEN Compared to the current market price of 2.08 USD, Inovio Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one INO stock under the best case scenario is HIDDEN Compared to the current market price of 2.08 USD, Inovio Pharmaceuticals, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
832 K REVENUE
-91.89%
-144 M OPERATING INCOME
46.21%
-135 M NET INCOME
51.71%
-124 M OPERATING CASH FLOW
42.48%
87.4 M INVESTING CASH FLOW
-20.29%
5 M FINANCING CASH FLOW
-93.90%
0 REVENUE
0.00%
-27.3 M OPERATING INCOME
17.62%
-87.8 B NET INCOME
-272287.24%
-84.4 B OPERATING CASH FLOW
-298934.45%
69.4 B INVESTING CASH FLOW
695958.40%
661 K FINANCING CASH FLOW
-98.00%
Balance Sheet Inovio Pharmaceuticals, Inc.
image
Current Assets 153 M
Cash & Short-Term Investments 145 M
Receivables 2.41 M
Other Current Assets 5.41 M
Non-Current Assets 19.8 M
Long-Term Investments 2.78 M
PP&E 14.5 M
Other Non-Current Assets 2.6 M
Current Liabilities 42.6 M
Accounts Payable 4.65 M
Short-Term Debt 19.2 M
Other Current Liabilities 18.7 M
Non-Current Liabilities 13 M
Long-Term Debt 11 M
Other Non-Current Liabilities 1.99 M
EFFICIENCY
Earnings Waterfall Inovio Pharmaceuticals, Inc.
image
Revenue 832 K
Cost Of Revenue 3.5 M
Gross Profit -2.67 M
Operating Expenses 145 M
Operating Income -144 M
Other Expenses -8.82 M
Net Income -135 M
RATIOS
-321.09% GROSS MARGIN
-321.09%
-17300.28% OPERATING MARGIN
-17300.28%
-16239.87% NET MARGIN
-16239.87%
-115.14% ROE
-115.14%
-78.13% ROA
-78.13%
-107.32% ROIC
-107.32%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Inovio Pharmaceuticals, Inc.
image
Net Income -135 M
Depreciation & Amortization 3.5 M
Capital Expenditures -321 K
Stock-Based Compensation 11.1 M
Change in Working Capital -10.3 M
Others 32.9 M
Free Cash Flow -125 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Inovio Pharmaceuticals, Inc.
image
Wall Street analysts predict an average 1-year price target for INO of $18 , with forecasts ranging from a low of $4 to a high of $40 .
INO Lowest Price Target Wall Street Target
4 USD 92.31%
INO Average Price Target Wall Street Target
18 USD 765.38%
INO Highest Price Target Wall Street Target
40 USD 1823.08%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0.069 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Inovio Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 year ago
Jun 05, 2023
Sell 3.19 K USD
Zoth Lota S.
Director
- 5700
0.56 USD
1 year ago
Mar 13, 2023
Sell 6.71 K USD
Weiner David B.
Director
- 5833
1.15 USD
1 year ago
Feb 27, 2023
Sell 14.9 K USD
Weiner David B.
Director
- 11668
1.28 USD
2 years ago
Aug 11, 2022
Sell 31.6 K USD
Weiner David B.
director:
- 11875
2.66 USD
2 years ago
Jul 20, 2022
Sell 4.5 K USD
BENITO SIMON X
director:
- 2000
2.25 USD
2 years ago
May 13, 2022
Sell 17.6 K USD
Weiner David B.
director:
- 9000
1.95 USD
2 years ago
May 13, 2022
Sell 7.13 K USD
Zoth Lota S.
director:
- 3600
1.98 USD
2 years ago
Mar 16, 2022
Sell 6.32 K USD
BENITO SIMON X
director:
- 2000
3.16 USD
2 years ago
Mar 11, 2022
Sell 13.1 K USD
Weiner David B.
director:
- 4083
3.2 USD
2 years ago
Mar 08, 2022
Sell 13.6 K USD
Weiner David B.
director:
- 4083
3.33 USD
3 years ago
Jan 19, 2022
Sell 8.54 K USD
BENITO SIMON X
Director
- 2000
4.27 USD
3 years ago
Jan 05, 2022
Sell 4.81 K USD
Zoth Lota S.
Director
- 961
5.01 USD
3 years ago
Aug 09, 2021
Sell 94.4 K USD
Humeau Laurent
Chief Scientific Officer
- 10317
9.15 USD
3 years ago
Jun 09, 2021
Sell 386 K USD
Shea Jacqueline Elizabeth
Chief Operating Officer
- 38535
10.01 USD
3 years ago
Jun 09, 2021
Sell 93.6 K USD
Humeau Laurent
Chief Scientific Officer
- 10318
9.07 USD
3 years ago
Jun 09, 2021
Sell 338 K USD
KIES PETER
CFO
- 33750
10.01 USD
3 years ago
Jun 03, 2021
Sell 80.3 K USD
KIES PETER
CFO
- 10000
8.03 USD
3 years ago
May 17, 2021
Sell 13.5 K USD
Zoth Lota S.
Director
- 2045
6.62 USD
3 years ago
May 17, 2021
Sell 20.2 K USD
Weiner David B.
Director
- 3045
6.62 USD
3 years ago
May 17, 2021
Sell 20.2 K USD
BENITO SIMON X
Director
- 3045
6.62 USD
3 years ago
Apr 21, 2021
Sell 85.2 K USD
KIES PETER
CFO
- 10000
8.52 USD
3 years ago
Apr 21, 2021
Sell 193 K USD
Weiner David B.
Director
- 22500
8.57 USD
3 years ago
Apr 21, 2021
Sell 34.9 K USD
Weiner David B.
Director
- 4083
8.54 USD
3 years ago
Apr 16, 2021
Sell 17.5 K USD
BENITO SIMON X
Director
- 2000
8.75 USD
3 years ago
Mar 26, 2021
Sell 42.2 K USD
Shea Jacqueline Elizabeth
Chief Operating Officer
- 4710
8.97 USD
3 years ago
Mar 16, 2021
Sell 20.8 K USD
BENITO SIMON X
Director
- 2000
10.41 USD
3 years ago
Mar 12, 2021
Sell 170 K USD
Shea Jacqueline Elizabeth
Chief Operating Officer
- 16881
10.06 USD
3 years ago
Mar 09, 2021
Sell 33.6 K USD
Weiner David B.
Director
- 3500
9.6003 USD
3 years ago
Mar 08, 2021
Sell 32.1 K USD
Weiner David B.
Director
- 3500
9.1814 USD
3 years ago
Feb 16, 2021
Sell 29.4 K USD
BENITO SIMON X
Director
- 2000
14.68 USD
3 years ago
Feb 01, 2021
Sell 1.5 M USD
Kim Jong Joseph
Chief Executive Officer
- 100000
15 USD
3 years ago
Feb 03, 2021
Sell 890 K USD
Kim Jong Joseph
Chief Executive Officer
- 62500
14.24 USD
3 years ago
Feb 01, 2021
Sell 337 K USD
Shea Jacqueline Elizabeth
Chief Operating Officer
- 22376
15.06 USD
3 years ago
Feb 01, 2021
Sell 89.4 K USD
Shea Jacqueline Elizabeth
Chief Operating Officer
- 5960
15 USD
3 years ago
Jan 28, 2021
Sell 201 K USD
Shea Jacqueline Elizabeth
Chief Operating Officer
- 16713
12.04 USD
3 years ago
Jan 27, 2021
Sell 269 K USD
Shea Jacqueline Elizabeth
Chief Operating Officer
- 22376
12.01 USD
3 years ago
Jan 27, 2021
Sell 71.8 K USD
Shea Jacqueline Elizabeth
Chief Operating Officer
- 5960
12.04 USD
4 years ago
Jan 15, 2021
Sell 301 K USD
KIES PETER
CFO
- 30000
10.0186 USD
4 years ago
Jan 05, 2021
Sell 9.11 K USD
Zoth Lota S.
Director
- 961
9.48 USD
4 years ago
Jan 04, 2021
Sell 24.8 K USD
BENITO SIMON X
Director
- 2750
9 USD
4 years ago
Dec 15, 2020
Sell 214 K USD
KIES PETER
CFO
- 20000
10.6853 USD
4 years ago
Dec 15, 2020
Sell 187 K USD
Weiner David B.
Director
- 17500
10.7058 USD
4 years ago
Nov 10, 2020
Sell 190 K USD
Humeau Laurent
Chief Scientific Officer
- 19466
9.75 USD
4 years ago
Aug 10, 2020
Sell 371 K USD
Humeau Laurent
Chief Scientific Officer
- 19467
19.0581 USD
4 years ago
Jul 30, 2020
Sell 2.11 M USD
Kim Jong Joseph
Chief Executive Officer
- 100000
21.1345 USD
4 years ago
Jul 15, 2020
Sell 873 K USD
KIES PETER
CFO
- 35000
24.9488 USD
4 years ago
Jun 30, 2020
Sell 928 K USD
KIES PETER
CFO
- 35000
26.5 USD
4 years ago
Jun 22, 2020
Sell 286 K USD
Humeau Laurent
Chief Scientific Officer
- 19467
14.7 USD
4 years ago
May 20, 2020
Sell 140 K USD
BENITO SIMON X
Director
- 8750
15.9536 USD
4 years ago
May 11, 2020
Sell 28.5 K USD
Weiner David B.
Director
- 2404
11.84 USD
4 years ago
Mar 10, 2020
Sell 32.6 K USD
Weiner David B.
Director
- 3500
9.32 USD
4 years ago
Mar 12, 2020
Sell 39 K USD
Weiner David B.
Director
- 3500
11.14 USD
4 years ago
Mar 09, 2020
Sell 63 K USD
Weiner David B.
Director
- 3500
18 USD
5 years ago
Jan 13, 2020
Bought 70 K USD
Kim Jong Joseph
Chief Executive Officer
+ 22500
3.11 USD
5 years ago
Aug 30, 2019
Bought 9.99 K USD
Humeau Laurent
Chief Scientific Officer
+ 4500
2.22 USD
5 years ago
Aug 01, 2019
Sell 44.5 K USD
Weiner David B.
Director
- 16352
2.72 USD
5 years ago
Jun 05, 2019
Bought 50 K USD
Humeau Laurent
Chief Scientific Officer
+ 20000
2.5 USD
5 years ago
May 31, 2019
Sell 1.22 M USD
Kim Jong Joseph
Chief Executive Officer
- 500000
2.4353 USD
5 years ago
May 31, 2019
Sell 1.2 M USD
Kim Jong Joseph
Chief Executive Officer
- 500000
2.4016 USD
5 years ago
Jun 03, 2019
Sell 1.91 M USD
Kim Jong Joseph
Chief Executive Officer
- 832848
2.2987 USD
5 years ago
Jun 03, 2019
Sell 685 K USD
Kim Jong Joseph
Chief Executive Officer
- 296705
2.3078 USD
5 years ago
May 21, 2019
Sell 331 K USD
Kim Jong Joseph
Chief Executive Officer
- 100000
3.31 USD
5 years ago
May 15, 2019
Sell 264 K USD
Kim Jong Joseph
Chief Executive Officer
- 75556
3.5 USD
5 years ago
May 16, 2019
Sell 214 K USD
Kim Jong Joseph
Chief Executive Officer
- 61212
3.5 USD
6 years ago
Nov 29, 2018
Sell 52.8 K USD
KIES PETER
CFO
- 10001
5.28 USD
6 years ago
Sep 12, 2018
Sell 263 K USD
Kim Jong Joseph
Chief Executive Officer
- 49060
5.37 USD
6 years ago
Jul 09, 2018
Sell 111 K USD
KIES PETER
CFO
- 25000
4.43 USD
6 years ago
Jul 10, 2018
Sell 44.5 K USD
KIES PETER
CFO
- 10000
4.45 USD
6 years ago
Apr 16, 2018
Sell 44.2 K USD
Weiner David B.
Director
- 9000
4.9114 USD
6 years ago
Apr 12, 2018
Sell 533 K USD
Kim Jong Joseph
Chief Executive Officer
- 103750
5.1387 USD
6 years ago
Apr 13, 2018
Sell 543 K USD
Kim Jong Joseph
Chief Executive Officer
- 107500
5.055 USD
6 years ago
Apr 12, 2018
Sell 19.6 K USD
BENITO SIMON X
Director
- 3750
5.2317 USD
7 years ago
May 25, 2017
Sell 64 K USD
Weiner David B.
Director
- 8000
8.002 USD
7 years ago
Mar 30, 2017
Sell 479 K USD
Kim Jong Joseph
Chief Executive Officer
- 73590
6.5051 USD
7 years ago
Mar 31, 2017
Sell 484 K USD
Kim Jong Joseph
Chief Executive Officer
- 73590
6.5739 USD
7 years ago
Mar 27, 2017
Bought 133 K USD
COLLINS MORTON
Director
+ 21300
6.253 USD
8 years ago
Aug 29, 2016
Sell 203 K USD
Sardesai Niranjan
Chief Operating Officer
- 21800
9.2997 USD
8 years ago
Jun 28, 2016
Bought 91.3 K USD
COLLINS MORTON
Director
+ 10000
9.1309 USD
8 years ago
May 18, 2016
Sell 64.8 K USD
BENITO SIMON X
Director
- 6250
10.371 USD
8 years ago
Apr 15, 2016
Bought 268 K USD
COLLINS MORTON
Director
+ 28000
9.57 USD
8 years ago
Apr 15, 2016
Bought 266 K USD
COLLINS MORTON
Director
+ 28000
9.4893 USD
8 years ago
Apr 15, 2016
Bought 58.6 K USD
COLLINS MORTON
Director
+ 6200
9.446 USD
8 years ago
Apr 15, 2016
Bought 39.7 K USD
COLLINS MORTON
Director
+ 4200
9.4571 USD
8 years ago
Apr 15, 2016
Bought 19 K USD
COLLINS MORTON
Director
+ 2000
9.4897 USD
9 years ago
Sep 30, 2015
Bought 22 K USD
Sardesai Niranjan
Chief Operating Officer
+ 4000
5.5 USD
9 years ago
Aug 14, 2015
Bought 43.3 K USD
BENITO SIMON X
Director
+ 6000
7.2096 USD
9 years ago
Apr 13, 2015
Bought 76.2 K USD
Cabrera Angel
Director
+ 8000
9.53 USD
10 years ago
Oct 09, 2014
Bought 40 K USD
KIES PETER
CFO
+ 3960
10.1 USD
10 years ago
Aug 21, 2014
Bought 40 K USD
COLLINS MORTON
Director
+ 4000
10.0112 USD
10 years ago
Aug 20, 2014
Bought 43.8 K USD
COLLINS MORTON
Director
+ 4500
9.7299 USD
10 years ago
Aug 20, 2014
Bought 44.6 K USD
COLLINS MORTON
Director
+ 4600
9.7062 USD
10 years ago
Aug 20, 2014
Bought 136 K USD
COLLINS MORTON
Director
+ 14000
9.7472 USD
10 years ago
Aug 20, 2014
Bought 16.5 K USD
COLLINS MORTON
Director
+ 1700
9.7299 USD
10 years ago
Aug 20, 2014
Bought 17.5 K USD
COLLINS MORTON
Director
+ 1800
9.7199 USD
10 years ago
Aug 12, 2014
Bought 2.26 M USD
Kim Jong Joseph
Chief Executive Officer
+ 250000
9.055 USD
10 years ago
Aug 12, 2014
Bought 22.2 K USD
Sardesai Niranjan
Chief Operating Officer
+ 2550
8.7 USD
10 years ago
Apr 15, 2014
Bought 56.2 K USD
Kim Jong Joseph
Chief Executive Officer
+ 25000
2.25 USD
11 years ago
Nov 13, 2013
Bought 91 K USD
COLLINS MORTON
Director
+ 50000
1.8205 USD
11 years ago
Nov 13, 2013
Bought 72.8 K USD
COLLINS MORTON
Director
+ 40000
1.8205 USD
11 years ago
Nov 13, 2013
Bought 182 K USD
COLLINS MORTON
Director
+ 100000
1.8205 USD
11 years ago
Nov 13, 2013
Bought 45.5 K USD
COLLINS MORTON
Director
+ 25000
1.8205 USD
11 years ago
Nov 13, 2013
Bought 20 K USD
COLLINS MORTON
Director
+ 11000
1.8205 USD
11 years ago
Nov 13, 2013
Bought 6.37 K USD
COLLINS MORTON
Director
+ 3500
1.8205 USD
11 years ago
Apr 16, 2013
Bought 33.5 K USD
Bagarazzi Mark
Chief Medical Officer
+ 60000
0.559 USD
11 years ago
Apr 02, 2013
Bought 45.2 K USD
Kim Jong Joseph
Chief Executive Officer
+ 90000
0.502 USD
11 years ago
Mar 22, 2013
Bought 21.6 K USD
Cabrera Angel
Director
+ 40000
0.5398 USD
11 years ago
Mar 20, 2013
Bought 13.3 K USD
Sardesai Niranjan
Chief Operating Officer
+ 25000
0.5331 USD
11 years ago
Mar 20, 2013
Bought 31.7 K USD
Kim Jong Joseph
Chief Executive Officer
+ 60000
0.528 USD
12 years ago
Jan 15, 2013
Bought 33.5 K USD
COLLINS MORTON
Director
+ 50000
0.6694 USD
12 years ago
Dec 03, 2012
Sell 13.8 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 25000
0.55 USD
12 years ago
Nov 28, 2012
Sell 54.4 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 96000
0.5666 USD
12 years ago
Nov 29, 2012
Sell 91.2 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 168700
0.5407 USD
12 years ago
Nov 29, 2012
Sell 137 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 250000
0.5483 USD
12 years ago
Nov 30, 2012
Sell 51 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 92800
0.55 USD
12 years ago
Nov 26, 2012
Sell 141 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 300000
0.4706 USD
12 years ago
Nov 27, 2012
Sell 318 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 650000
0.4898 USD
12 years ago
Nov 21, 2012
Sell 109 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 230000
0.4728 USD
12 years ago
Nov 23, 2012
Sell 58.7 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 123900
0.4737 USD
12 years ago
Nov 19, 2012
Sell 105 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 220099
0.4774 USD
12 years ago
Nov 20, 2012
Sell 60 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 126800
0.473 USD
12 years ago
Nov 15, 2012
Sell 232 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 500000
0.4646 USD
12 years ago
Nov 16, 2012
Sell 242 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 500000
0.4836 USD
12 years ago
Nov 13, 2012
Sell 120 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 222550
0.5401 USD
12 years ago
Nov 14, 2012
Sell 209 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 400000
0.5221 USD
12 years ago
Nov 08, 2012
Sell 306 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 500000
0.6124 USD
12 years ago
Nov 09, 2012
Sell 230 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 400000
0.5744 USD
12 years ago
Nov 12, 2012
Sell 85 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 148192
0.5738 USD
12 years ago
Nov 01, 2012
Sell 23 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 31979
0.72 USD
12 years ago
Oct 26, 2012
Sell 7.05 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 9788
0.72 USD
12 years ago
Oct 24, 2012
Sell 2.1 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 2900
0.725 USD
12 years ago
Oct 25, 2012
Sell 7.38 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 10250
0.7203 USD
12 years ago
Oct 22, 2012
Sell 71.5 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 100000
0.715 USD
12 years ago
Oct 23, 2012
Sell 286 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 202000
1.4179 USD
12 years ago
Oct 12, 2012
Sell 9.58 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 13400
0.715 USD
12 years ago
Oct 15, 2012
Sell 14.5 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 20286
0.715 USD
12 years ago
Oct 10, 2012
Sell 230 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 319000
0.7202 USD
12 years ago
Oct 11, 2012
Sell 53 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 75200
0.7049 USD
12 years ago
Oct 11, 2012
Sell 122 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 169700
0.7163 USD
12 years ago
Aug 15, 2012
Bought 44.2 K USD
Cabrera Angel
Director
+ 75000
0.59 USD
12 years ago
Jun 13, 2012
Bought 6.09 K USD
Kim Jong Joseph
Chief Executive Officer
+ 15000
0.406 USD
12 years ago
Jun 05, 2012
Bought 10.2 K USD
Kim Jong Joseph
Chief Executive Officer
+ 25000
0.41 USD
12 years ago
Jun 05, 2012
Bought 10.2 K USD
KIES PETER
CFO
+ 25000
0.41 USD
12 years ago
May 16, 2012
Bought 4.5 K USD
Sardesai Niranjan
Chief Operating Officer
+ 10000
0.45 USD
12 years ago
May 10, 2012
Bought 24 K USD
Kim Jong Joseph
Chief Executive Officer
+ 50000
0.48 USD
12 years ago
Mar 22, 2012
Bought 11.8 K USD
Kim Jong Joseph
Chief Executive Officer
+ 19116
0.6185 USD
12 years ago
Mar 21, 2012
Bought 19.1 K USD
Kim Jong Joseph
Chief Executive Officer
+ 30884
0.617 USD
13 years ago
Dec 13, 2011
Sell 205 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 535000
0.3824 USD
13 years ago
Dec 09, 2011
Sell 158 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 400000
0.3953 USD
13 years ago
Dec 12, 2011
Sell 139 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 360000
0.3868 USD
13 years ago
Dec 07, 2011
Sell 120 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 300000
0.3991 USD
13 years ago
Dec 07, 2011
Sell 203 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 503000
0.4026 USD
13 years ago
Dec 05, 2011
Sell 19.9 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 45200
0.44 USD
13 years ago
Dec 06, 2011
Sell 61.5 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 150000
0.41 USD
13 years ago
Dec 06, 2011
Sell 42 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 100000
0.42 USD
13 years ago
Dec 01, 2011
Sell 286 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 670000
0.4272 USD
13 years ago
Dec 01, 2011
Sell 244 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 570000
0.4285 USD
13 years ago
Dec 02, 2011
Sell 72.1 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 170000
0.4239 USD
13 years ago
Dec 02, 2011
Sell 108 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 250000
0.43 USD
13 years ago
Oct 17, 2011
Sell 1.74 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 2800
0.62 USD
13 years ago
Oct 18, 2011
Sell 900 USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 1500
0.6 USD
13 years ago
Oct 11, 2011
Sell 5.38 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 8900
0.6048 USD
13 years ago
Oct 12, 2011
Sell 12 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 19950
0.6023 USD
13 years ago
Oct 06, 2011
Sell 120 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 200000
0.6 USD
13 years ago
Oct 07, 2011
Sell 14.6 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 23500
0.62 USD
13 years ago
Oct 04, 2011
Bought 8.12 K USD
KIES PETER
CFO
+ 16250
0.5 USD
13 years ago
Oct 04, 2011
Bought 1.48 K USD
KIES PETER
CFO
+ 2900
0.51 USD
13 years ago
Oct 05, 2011
Bought 9.63 K USD
KIES PETER
CFO
+ 18000
0.535 USD
13 years ago
Sep 30, 2011
Bought 14 K USD
Kim Jong Joseph
Chief Executive Officer
+ 25000
0.56 USD
13 years ago
Sep 30, 2011
Sell 113 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 200000
0.5665 USD
13 years ago
Sep 28, 2011
Sell 82.4 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 141000
0.5843 USD
13 years ago
Sep 28, 2011
Sell 42.6 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 72300
0.589 USD
13 years ago
Sep 29, 2011
Sell 229 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 400000
0.5714 USD
13 years ago
Sep 26, 2011
Sell 47.2 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 76000
0.6211 USD
13 years ago
Sep 27, 2011
Sell 112 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 180000
0.622 USD
13 years ago
Sep 22, 2011
Sell 109 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 166000
0.656 USD
13 years ago
Sep 23, 2011
Sell 127 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 202000
0.6284 USD
13 years ago
Sep 02, 2011
Bought 6.9 K USD
Kim Jong Joseph
Chief Executive Officer
+ 10000
0.69 USD
13 years ago
Sep 01, 2011
Bought 22.4 K USD
Kim Jong Joseph
Chief Executive Officer
+ 31887
0.704 USD
13 years ago
Aug 26, 2011
Bought 2.97 K USD
Kim Jong Joseph
Chief Executive Officer
+ 4500
0.66 USD
13 years ago
Aug 26, 2011
Bought 2.41 K USD
Kim Jong Joseph
Chief Executive Officer
+ 3650
0.66 USD
13 years ago
Aug 26, 2011
Bought 7.83 K USD
Kim Jong Joseph
Chief Executive Officer
+ 11871
0.66 USD
13 years ago
Aug 24, 2011
Bought 9.83 K USD
Kim Jong Joseph
Chief Executive Officer
+ 15000
0.6553 USD
13 years ago
Aug 24, 2011
Bought 23.3 K USD
Kim Jong Joseph
Chief Executive Officer
+ 35000
0.666 USD
13 years ago
Aug 24, 2011
Bought 17.8 K USD
Kim Jong Joseph
Chief Executive Officer
+ 26659
0.666 USD
13 years ago
Aug 23, 2011
Bought 12.9 K USD
Kim Jong Joseph
Chief Executive Officer
+ 20000
0.6464 USD
13 years ago
Aug 23, 2011
Bought 32.8 K USD
COLLINS MORTON
Director
+ 50000
0.6563 USD
13 years ago
Aug 11, 2011
Bought 31.5 K USD
COLLINS MORTON
Director
+ 50000
0.6299 USD
13 years ago
Jul 06, 2011
Bought 14.4 K USD
DHILLON AVTAR S
Executive Chairman
+ 20000
0.72 USD
13 years ago
Jun 30, 2011
Sell 915 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 1500000
0.6101 USD
13 years ago
Jun 28, 2011
Sell 1.15 M USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 2000000
0.5773 USD
13 years ago
Jun 29, 2011
Sell 295 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 500000
0.5901 USD
13 years ago
Jun 29, 2011
Bought 29.3 K USD
COLLINS MORTON
Director
+ 50000
0.586 USD
13 years ago
Jun 24, 2011
Bought 11.3 K USD
BENITO SIMON X
Director
+ 20000
0.5656 USD
13 years ago
Jun 24, 2011
Bought 57.6 K USD
COLLINS MORTON
Director
+ 100000
0.5761 USD
13 years ago
Jun 16, 2011
Bought 13.7 K USD
Kim Jong Joseph
Chief Executive Officer
+ 21900
0.625 USD
13 years ago
Jun 24, 2011
Bought 13.6 K USD
KIES PETER
CFO
+ 24000
0.5676 USD
13 years ago
Jun 16, 2011
Bought 13.7 K USD
Kim Jong Joseph
Chief Executive Officer
+ 21900
0.625 USD
13 years ago
May 13, 2011
Sell 230 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 250000
0.92 USD
13 years ago
May 11, 2011
Sell 92.5 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 100000
0.9249 USD
13 years ago
May 09, 2011
Sell 182 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 200000
0.9122 USD
13 years ago
Apr 18, 2011
Sell 251 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 250000
1.0024 USD
13 years ago
Mar 30, 2011
Sell 292 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 250000
1.17 USD
13 years ago
Feb 02, 2011
Sell 536 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 400000
1.3411 USD
13 years ago
Feb 02, 2011
Sell 143 K USD
MARXE AUSTIN W & GREENHOUSE DAVID M
10 percent owner
- 105000
1.362 USD
16 years ago
Feb 01, 2008
Bought 65.2 K USD
DHILLON AVTAR S
President & CEO
+ 75000
0.87 USD
18 years ago
Dec 20, 2006
Sell 14.1 K USD
GOODENEW ROBERT S
V.P. Corporate Development
- 4400
3.2 USD
18 years ago
Dec 19, 2006
Sell 138 K USD
GOODENEW ROBERT S
V.P. Corporate Development
- 43100
3.2 USD
20 years ago
Nov 19, 2004
Sell 114 K USD
GOODENEW ROBERT S
V.P. Corporate Development
- 32500
3.5 USD
20 years ago
Nov 19, 2004
Sell 26.6 K USD
GOODENEW ROBERT S
V.P. Corporate Development
- 7500
3.55 USD
20 years ago
Nov 11, 2004
Sell 852 USD
RABUSSAY DIETMAR P
V.P. Research & Development
- 250
3.41 USD
20 years ago
Oct 14, 2004
Bought 16.9 K USD
DHILLON AVTAR S
President & CEO
+ 6600
2.56 USD
20 years ago
Oct 14, 2004
Bought 1.02 K USD
DHILLON AVTAR S
President & CEO
+ 400
2.55 USD
20 years ago
Oct 14, 2004
Bought 7.32 K USD
DHILLON AVTAR S
President & CEO
+ 3000
2.44 USD
20 years ago
Sep 17, 2004
Bought 9.06 K USD
HEPPELL JAMES L
Director
+ 1029
8.8 USD
20 years ago
Sep 17, 2004
Bought 23.5 K USD
HEPPELL JAMES L
Director
+ 2
11764.71 USD
20 years ago
Sep 15, 2004
Bought 4.52 K USD
GOODENEW ROBERT S
V.P. Corporate Development
+ 514
8.8 USD
20 years ago
Sep 15, 2004
Bought 5.88 K USD
GOODENEW ROBERT S
V.P. Corporate Development
+ 1
5882.35 USD
20 years ago
Sep 16, 2004
Bought 9.06 K USD
ESMAIL TAZDIN
Director
+ 1029
8.8 USD
20 years ago
Sep 16, 2004
Bought 23.5 K USD
ESMAIL TAZDIN
Director
+ 2
11764.71 USD
20 years ago
Sep 16, 2004
Bought 9.06 K USD
Bandali Riaz Amirali
Director
+ 1029
8.8 USD
20 years ago
Sep 16, 2004
Bought 23.5 K USD
Bandali Riaz Amirali
Director
+ 2
11764.71 USD
20 years ago
Sep 16, 2004
Bought 4.52 K USD
RABUSSAY DIETMAR P
V.P. Research & Development
+ 514
8.8 USD
20 years ago
Sep 16, 2004
Bought 5.88 K USD
RABUSSAY DIETMAR P
V.P. Research & Development
+ 1
5882.35 USD
20 years ago
Sep 14, 2004
Bought 9.06 K USD
DHILLON AVTAR S
President & CEO
+ 1029
8.8 USD
20 years ago
Sep 14, 2004
Bought 23.5 K USD
DHILLON AVTAR S
President & CEO
+ 2
11764.71 USD
20 years ago
Sep 14, 2004
Bought 9.06 K USD
THEEUWES FELIX
Director
+ 1029
8.8 USD
20 years ago
Sep 14, 2004
Bought 23.5 K USD
THEEUWES FELIX
Director
+ 2
11764.71 USD
20 years ago
Sep 14, 2004
Bought 4.52 K USD
McHugh George F. III
Vice President, Operations
+ 514
8.8 USD
20 years ago
Sep 14, 2004
Bought 5.88 K USD
McHugh George F. III
Vice President, Operations
+ 1
5882.35 USD
20 years ago
Sep 14, 2004
Bought 13.6 K USD
LARSON EUGENE A
Director
+ 1544
8.8 USD
20 years ago
Sep 14, 2004
Bought 52.9 K USD
LARSON EUGENE A
Director
+ 3
17647.06 USD
20 years ago
Sep 14, 2004
Bought 13.6 K USD
BENITO SIMON X
Director
+ 1544
8.8 USD
20 years ago
Sep 14, 2004
Bought 52.9 K USD
BENITO SIMON X
Director
+ 3
17647.06 USD
20 years ago
Sep 14, 2004
Bought 4.52 K USD
KIES PETER
CFO
+ 514
8.8 USD
20 years ago
Sep 14, 2004
Bought 5.88 K USD
KIES PETER
CFO
+ 1
5882.35 USD
21 years ago
Dec 22, 2003
Sell 23.2 K USD
RABUSSAY DIETMAR P
V.P. Research & Development
- 20000
1.16 USD
7. News
Gold Down Over 1%; Inovio Pharmaceuticals Shares Plummet U.S. stocks traded mixed toward the end of trading, with the S&P 500 edging lower on Friday. benzinga.com - 1 month ago
INOVIO Announces Pricing of $30 Million Public Offering PLYMOUTH MEETING, Pa. , Dec. 13, 2024 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock and accompanying warrants to purchase 10,000,000 shares of its common stock at an exercise price of $3.76 per share of common stock, at a combined public offering price of $3.00 per share of common stock and accompanying warrant. prnewswire.com - 1 month ago
INOVIO Announces Proposed Public Offering PLYMOUTH MEETING, Pa. , Dec. 12, 2024 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of its common stock, in an underwritten public offering. prnewswire.com - 1 month ago
New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial Data from a retrospective trial evaluating the longer-term benefit of INO-3107 to patients with Recurrent Respiratory Papillomatosis (RRP) involved in a Phase 1/2 trial showed the number of patients who met the criteria for a Complete Response (CR) increased to 50% by the end of year 2 and to 54% in year 3, compared to 28% by the end of the initial 52-week trial 95% of patients in the retrospective trial (RRP-002) maintained or enhanced their original Overall Response Rate (ORR) reported in the Phase 1/2 trial (RRP-001) by the end of year 2; 86% of patients maintained or enhanced ORR into year 3 New durability data will help inform re-dosing strategy focused on long-term elimination or reduction in the need for surgery to treat RRP disease INOVIO plans to present data at future scientific conferences and submit for publication in peer-reviewed journals PLYMOUTH MEETING, Pa. , Dec. 3, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced data from a retrospective trial showing that the number of RRP patients meeting the criteria for a Complete Response increased to 50% by the end of the second year following initial treatment with INO-3107 in a previously reported Phase 1/2 52-week trial where the Complete Response rate was 28%. prnewswire.com - 1 month ago
INOVIO Reports Inducement Grant Under Inducement Plan PLYMOUTH MEETING, Pa. , Nov. 29, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan"). prnewswire.com - 1 month ago
European And US Vaccine Stocks Are Under Pressure - Here's WHy Some large European and U.S. vaccine maker stocks have fallen in reaction to Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services. benzinga.com - 2 months ago
Inovio Pharmaceuticals, Inc. (INO) Q3 2024 Earnings Call Transcript Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q3 2024 Earnings Call Transcript November 14, 2024 4:30 PM ET Company Participants Thomas Hong - Manager of IR Jacqui Shea - President and CEO Mike Sumner - CMO Steve Egge - CCO Peter Kies - CFO Matthew Morrow - VP of Translational Sciences Conference Call Participants Jay Olson - Oppenheimer Roy Buchanan - Citizens JMP Sudan Loganathan - Stephens Liang Cheng - Jefferies Operator Good afternoon, ladies and gentlemen, and welcome to the Inovio Third Quarter 2024 Financial Results Conference Call. At this time, all lines are in a listen-only mode. seekingalpha.com - 2 months ago
INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights New immunology data for INO-3107 supporting proposed mechanism of action presented at several recent conferences  Data showed ability of INO-3107 to induce an antigen-specific cytotoxic T cell response against HPV-6 and HPV-11 and drive recruitment of T cells into airway tissues and papilloma Data showed INO-3107 induced expansion of new clonal T cells that infiltrate airway tissues and correspond with reduction of surgeries for RRP patients observed in Phase 1/2 trial Continued progress on preparing regulatory submissions for INO-3107 All non-device BLA modules on track for completion by end of 2024 BLA submission remains targeted for mid-2025 PLYMOUTH MEETING, Pa. , Nov. 14, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the third quarter of 2024 and provided an update on recent company developments. prnewswire.com - 2 months ago
Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial New immunology data shows INO-3107 induced an expansion of new clonal T cells in blood that were not detectable prior to treatment New clonal T cells in the blood travelled to papilloma and airway tissues and generated an inflammatory and anti-viral response consistent with a reduced need for surgeries for patients with recurrent respiratory papillomatosis (RRP) caused by HPV-6 and HPV-11 Data supporting mechanism of action for INO-3107 to be presented at 36th International Papillomavirus Conference in Edinburgh, UK PLYMOUTH MEETING, Pa. , Nov. 13, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced new immunology data that supports the clinical activity of its lead product candidate, INO-3107, that was previously observed in a Phase 1/2 trial of RRP patients. prnewswire.com - 2 months ago
INOVIO to Present at Upcoming Scientific Conferences PLYMOUTH MEETING, Pa. , Nov. 6, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conferences: 36th International Papillomavirus Conference (Edinburgh, UK; November 12-15) Presentation and poster by Dr. Matthew Morrow, VP of Translational Sciences Abstract Title: Treatment of recurrent respiratory papillomatosis with INO-3107 induces significant enrichment in hallmark interferon alpha, interferon gamma and inflammatory molecular signatures in papilloma tissue of responders Poster by Dr. Jeffrey Skolnik, SVP of Clinical Development Abstract Title: Clinical response to INO-3107 treatment for recurrent respiratory papillomatosis is associated with CD4 and CD8 T-Cell activity and cytotoxicity in patient airways Vaccines Summit (Boston, MA; November 13-15) Keynote presentation by Dr. Dave Liebowitz, SVP Early-Stage Clinical Development Abstract Title: DNA Medicines Vaccine Platform for both Prophylactic and Therapeutic Applications: Case Studies in Ebola and Recurrent Respiratory Papillomatosis Abstracts from these conferences will be made available on INOVIO's website following each presentation. prnewswire.com - 2 months ago
INOVIO to Report Third Quarter 2024 Financial Results on November 14, 2024 PLYMOUTH MEETING, Pa. , Nov. 6, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that third quarter 2024 financial results will be released after the market close on November 14, 2024. prnewswire.com - 2 months ago
INOVIO Announces New Data at Scientific Conferences for Lead Candidate, INO-3107, as a Potential Treatment for RRP American Association for Cancer Research (AACR) Special Conference: Tumor Immunology and Immunotherapy : New immunology data showed ability of INO-3107 to induce an antigen-specific T cell response against HPV-6 and HPV-11 and drive recruitment of T cells into airway tissues and papilloma International Society of Vaccines Conference : Full safety and efficacy data from Phase 1/2 clinical study in patients with Recurrent Respiratory Papillomatosis (RRP) indicated that INO-3107 was well tolerated and immunogenic; 81% of patients in the trial required fewer surgeries post-treatment when compared to baseline PLYMOUTH MEETING, Pa. , Oct. 21, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the presentation of new data at scientific conferences for its lead candidate, INO-3107, for which the company is preparing a Biologics License Application for targeted submission in mid-2025 under the U.S. Food and Drug Administration's Accelerated Approval Pathway Program. prnewswire.com - 2 months ago
8. Profile Summary

Inovio Pharmaceuticals, Inc. INO

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 75.1 M
Dividend Yield 0.00%
Description Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Contact 660 West Germantown Pike, Plymouth Meeting, PA, 19462 https://www.inovio.com
IPO Date Dec. 8, 1998
Employees 127
Officers Mr. Shawn D. Bridy M.A., M.B.A. Senior Vice President of Business Development Dr. Jeffrey Skolnik Senior Vice President of Clinical Development Dr. Jacqueline E. Shea Ph.D. Chief Executive Officer, President & Director Mr. Peter D. Kies Chief Financial Officer Mr. Robert L. Crotty J.D. General Counsel & Chief Compliance Officer Thomas Hong Manager of Investor Relations Dr. Laurent M. Humeau Ph.D. Chief Scientific Officer & Chairman of the Scientific Advisory Board Mr. E. J. Brandreth MBA Senior Vice President of Quality Assurance Mr. Robert J. Juba Jr. Senior Vice President of Biological Manufacturing & Clinical Supply Management Dr. David Liebowitz M.D., Ph.D. Senior Vice President of Early-Stage Clinical Development